[vc_row][vc_column width=”2\/3″][vc_single_image image=”2577″ img_size=”full”][vc_column_text]<\/p>\n
The members of the \u201cconect4children\u201d (c4c) initiative today announced the start of a large collaborative paediatric network that will facilitate the development of new drugs and other therapies for the entire paediatric population in Europe. The conect4children (collaborative network for E<\/u>uropean c<\/u>linical t<\/u>rials for children, (c4c) <\/strong>consortium aims to enhance the competitiveness of Europe as a critical region for developing medicines for children by using existing expertise, patient access and developing common processes to be applied to disease natural history studies, registries, studies of new therapies and comparisons of existing therapies.<\/p>\n The consortium is a novel collaboration between academic and private sectors that includes 33 academic and 10 industry partners from 20 European countries, more than 50 third parties and around 500 affiliated partners.<\/p>\n The six-year project, comprised of a multidisciplinary public-private consortium, brings together key stakeholders across academia and industry. It is a pioneering opportunity to build capacity for the management of multinational paediatric clinical trials across Europe whilst ensuring the voices of children, young people and their families are heard. Strong links with regulators will be established.<\/p>\n There are many scientific and operational challenges faced by both pharmaceutical companies and academia when running paediatric clinical trials. According to Prof. Carlo Giaquinto of Fondazione PENTA Onlus and University of Padova, who coordinates the project, \u201cc4c<\/strong> will address critical problems with the design, implementation and operational conduct of paediatric clinical trials, such as fragmented and redundant efforts between sponsors, sites and countries; the paucity of patients available for study in many paediatric indications and the need for multiple capable sites and expertise to make trials successful.\u201d<\/p>\n This project aims to generate a sustainable infrastructure that optimises the delivery of clinical trials in children through:<\/p>\n One of the key goals of the project is to support the use of innovative trial designs and new quantitative methods to foster development of new innovative medicines and to support development in rare paediatric diseases and high medical need area<\/p>\n \u201cChildren must have access to innovative medical therapies that have been developed with the same degree of urgency and rigor as those for adults,\u201d said Joanne Waldstreicher,\u00a0MD,\u00a0Chief Medical Officer, Johnson & Johnson. \u201cWith conect4children in Europe joining in this effort, complementing work under way with I-ACT for Children in the United States, we will be able to\u00a0accelerate the availability of high quality scientific data that can improve the safe and effective use of therapies in children.”<\/p>\n \u201cClinical trials with medicinal products for paediatric use are one of the most sensitive areas in science \u2013 both from a medical and an ethical perspective\u201d, said Dr. Michael Devoy, Chief Medical Officer of Bayer. \u201cImproving the clinical trial infrastructure is an import step in enabling children to take part in medical progress\u201d.<\/p>\n Dr. Mark Turner, Co-coordinator of the project, University of Liverpool, stated: \u201cThis network will have a significant impact on how we develop much-needed innovative and improved medicines for babies, children and young people. A number of collaborations built up over the past decade will contribute to this pan-European research network. The University of Liverpool is proud to be collaborating with institutions and research networks across Europe\u201d<\/p>\n With a budget of about 140 Mio\u20ac (IMI2 support of 67 Mio\u20ac and industry partners\u2019 in-kind contribution of 73 Mio\u20ac), c4c<\/strong> is one of the biggest initiatives funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement n \u00ba 777389. The Innovative Medicines Initiative 2 Joint Undertaking is Europe\u2019s biggest Public Private Partnership and is funded jointly by the European Union\u00b4s Horizon 2020 research and innovation programme and the European pharmaceutical industry (represented by\u00a0EFPIA, the European Federation of Pharmaceutical Industries and Associations).<\/p>\n The parties involved<\/strong><\/p>\n The project is coordinated and led by: Fondazione PENTA \u2013 for the treatment and care of children with HIV \u2013 ONLUS, The University of Liverpool, Janssen Pharmaceutica NV, Bayer AG<\/p>\n Other partners are: Ospedale Pediatrico Bambino Ges\u00f9; EURORDIS \u2013 European Organisation for Rare Diseases Association; European Cystic Fibrosis Society; Stichting Katholieke Universiteit; Swiss Clinical Trial Organisation Verein; Associa\u00e7\u00e3o para Investiga\u00e7\u00e3o e Desenvolvimento da Faculdade de Medicina; Istituto Giannina Gaslini; University College London; SIOP Europe ASBL; Tartu Ulikool; Okids GMBH; University of Newcastle upon Tyne; Universiteit Gent; Universitaetsklinikum Heidelberg; Aristotelio Panepistimio Thessalonikis; Instytut Pomnik Centrum Zdrowia Dziecka; Helse Bergen HF*Haukeland University Hospital; ECNP Research & Scholarship Foundation; Robert Bosch Gesellschaft fur Medizinische Forschung MBH; University College Cork\u2013 National University of Ireland, Cork; Karolinska Institutet; Fundacio Sant Joan de Deu; Servizo Galego de Saude; Gyermekgy\u00f3gy\u00e1szati Klinikai Vizsg\u00e1l\u00f3i H\u00e1l\u00f3zat; Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus; ECRIN European Clinical Research Infrastructure Network; The Hospital District of Helsinki and Uusimaa; Institut National de la Sante et de la Recherche Medicale; HSK DR Horst Schmidt Kliniken Wiesbaden Gmbh; ARSENAL.IT-Centro Veneto Ricerca e Innovazione per la Sanit\u00e0 Digitale; Univerzita Karlova; Sanofi-Aventis Recherche & D\u00e9veloppement; Eli Lilly and Company Limited; UCB Biopharma SPRL; Novartis Pharma AG; Institut de Recherches Internationales Servier; GlaxoSmithKline Research and Development LTD.; Pfizer Limited; F. Hoffmann \u2013 La Roche AG<\/p>\n The full list of organisations involved in the project can also be found at the c4c<\/strong> webpage www.conect4children.org<\/a><\/p>\n Project Office\/General Enquires: <\/strong>Email us. communication@conect4children.org<\/a><\/p>\n Disclaimer<\/strong> H2020-JTI-IMI2-2016-10. Proposal: 777389<\/p>\n [\/vc_column_text][vc_empty_space][\/vc_column][vc_column width=”1\/3″][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":" [vc_row][vc_column width=”2\/3″][vc_single_image image=”2577″ img_size=”full”][vc_column_text] Launch of a new public-private partnership to improve clinical trial infrastructure to facilitate the development of […]<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-fullwidth.php","meta":{"footnotes":""},"class_list":["post-2576","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/pages\/2576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/comments?post=2576"}],"version-history":[{"count":1,"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/pages\/2576\/revisions"}],"predecessor-version":[{"id":2578,"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/pages\/2576\/revisions\/2578"}],"wp:attachment":[{"href":"https:\/\/mcrn.hu\/en\/wp-json\/wp\/v2\/media?parent=2576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\nThis communication reflects the views of the c4c<\/strong> Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein<\/p>\n